Company: CMND
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005519
Chunk: 14

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: POS AM
Chunk 14
---
 securities convertible into
common shares. Any such issuance could result in substantial dilution to our existing shareholders and could cause our share price to
decline.

Part of our operations are conducted in Israel. Conditions in Israel, including the recent attack by Hamas and other terrorist organizations and Israel’s war against them, may affect our operations.

Our operations are located in the State of
Israel. In addition, certain of our key employees and officers, including our chief executive officer, are residents of Israel. Accordingly,
political, economic and military conditions in the Middle East may affect our business directly. Since the establishment of the State
of Israel in 1948, a number of armed conflicts have occurred between Israel and its neighboring countries and terrorist organizations
active in the region, including Hamas (an Islamist militia and political group in the Gaza Strip) and Hezbollah (an Islamist militia
and political group in Lebanon).

In particular, in October 2023, Hamas terrorists
infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas
also launched extensive rocket attacks on the Israeli population and industrial centers located along Israel’s border with the
Gaza Strip and in other areas within the State of Israel. These attacks resulted in thousands of deaths and injuries, and Hamas additionally
kidnapped many Israeli civilians and soldiers. As a result of the events of October 7, 2023, the Israeli government declared that the
country was at war and the Israeli military began to call-up reservists for active duty. As of January 21, 2025, none of our directors,
officers or employees are serving in active or reserve duty. Military service call ups that result in absences of personnel from us for
an extended period of time may materially and adversely affect our business, prospects, financial condition and results of operations.

Since the commencement of these events, there
have been continued hostilities along Israel’s northern border with with the Hezbollah terror organization), with the Houthis in
Yemen and on other fronts with various extremist groups in the region, such as various rebel militia groups in Syria and Iraq. In October 2024, Israel began limited ground operations against Hezbollah
in Lebanon, and in November 2024, a ceasefire was brokered between Israel and Hezbollah. It is possible that hostilities with Iran, Hezbollah, the Houthis and
Syria will escalate, and that other terrorist organizations, including Palestinian military organizations in the West Bank, will join
the hostilities. In